Related Experiment Video

Updated: Oct 13, 2026

Epigenome-Wide CRISPR-Cas9-Based Knockout Screens on Chemoresistant Cells
12:25

Epigenome-Wide CRISPR-Cas9-Based Knockout Screens on Chemoresistant Cells

Published on: July 21, 2026

Evaluating limited specificity of drug pumps reduced relative resistance in human MDR phenotypes

A P Jongsma1, A Riethorst, J Lankelma

  • 1Division of Molecular Biology, the Netherlands Cancer Institute, Amsterdam.

European Journal of Biochemistry
|August 22, 2000
PubMed

Insights

Drug efflux pumps influence multidrug resistance (MDR). This study uses reduced relative resistance (RRR) to explore if varying P-glycoprotein levels explain diverse MDR phenotypes, finding other factors are also involved.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) in humans is a complex phenomenon.
  • P-glycoprotein, encoded by the MDR1 gene, is a key drug efflux pump implicated in MDR.
  • Previous work introduced reduced relative resistance (RRR) to characterize drug efflux pumps.

Purpose of the Study:

  • To investigate if variable levels of P-glycoprotein contribute to the diversity of human MDR phenotypes.
  • To analyze MDR phenotypes in cell lines with differential expression of MDR1 and MDR3 genes.
  • To assess the applicability of the RRR method to literature-reported MDR phenotypes.

Main Methods:

  • Analysis of drug resistance phenotypes in human cell lines overexpressing MDR1 and/or MDR3.
  • Calculation of reduced relative resistance (RRR) values for experimental and literature data.
  • Comparative analysis of RRR values across different cell lines and phenotypes.

Main Results:

  • The study found that variable P-glycoprotein levels only partially explain the observed diversity in MDR phenotypes.
  • Differences in plasma membrane permeability between cell line families contribute to phenotypic variation.
  • Results suggest that mechanisms beyond P-glycoprotein expression are necessary to account for classical MDR diversity.

Conclusions:

  • The phenotypic diversity of classical multidrug resistance is multifactorial, not solely due to MDR1/P-glycoprotein levels.
  • Alternative MDR phenotypes may arise from MDR1 activity modulated by other cellular factors.
  • The RRR methodology shows potential for characterizing other nonspecific enzymes or pumps.

More Related Videos

Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System05:06

Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Published on: January 5, 2024

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...